Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL

GD. Garland, SP. Ducray, L. Jahangiri, P. Pucci, GA. Amos Burke, J. Monahan, R. Lai, O. Merkel, AI. Schiefer, L. Kenner, AJ. Bannister, SD. Turner

. 2021 ; 14 (1) : . [pub] 20211229

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010365

Grantová podpora
C9685/A25117 Cancer Research UK - United Kingdom
675712 Marie Curie - United Kingdom

Anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy driven in many cases by the product of a chromosomal translocation, nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). NPM-ALK activates a plethora of pathways that drive the hallmarks of cancer, largely signalling pathways normally associated with cytokine and/or T-cell receptor-induced signalling. However, NPM-ALK is also located in the nucleus and its functions in this cellular compartment for the most part remain to be determined. We show that ALCL cell lines and primary patient tumours express the transcriptional activator BRG1 in a NPM-ALK-dependent manner. NPM-ALK regulates expression of BRG1 by post-translational mechanisms dependent on its kinase activity, protecting it from proteasomal degradation. Furthermore, we show that BRG1 drives a transcriptional programme associated with cell cycle progression. In turn, inhibition of BRG1 expression with specific shRNA decreases cell viability, suggesting that it may represent a key therapeutic target for the treatment of ALCL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010365
003      
CZ-PrNML
005      
20220425131815.0
007      
ta
008      
220420s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14010151 $2 doi
035    __
$a (PubMed)35008316
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Garland, Gavin D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK
245    10
$a BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL / $c GD. Garland, SP. Ducray, L. Jahangiri, P. Pucci, GA. Amos Burke, J. Monahan, R. Lai, O. Merkel, AI. Schiefer, L. Kenner, AJ. Bannister, SD. Turner
520    9_
$a Anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy driven in many cases by the product of a chromosomal translocation, nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). NPM-ALK activates a plethora of pathways that drive the hallmarks of cancer, largely signalling pathways normally associated with cytokine and/or T-cell receptor-induced signalling. However, NPM-ALK is also located in the nucleus and its functions in this cellular compartment for the most part remain to be determined. We show that ALCL cell lines and primary patient tumours express the transcriptional activator BRG1 in a NPM-ALK-dependent manner. NPM-ALK regulates expression of BRG1 by post-translational mechanisms dependent on its kinase activity, protecting it from proteasomal degradation. Furthermore, we show that BRG1 drives a transcriptional programme associated with cell cycle progression. In turn, inhibition of BRG1 expression with specific shRNA decreases cell viability, suggesting that it may represent a key therapeutic target for the treatment of ALCL.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ducray, Stephen P $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK $1 https://orcid.org/0000000164071906
700    1_
$a Jahangiri, Leila $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK $u Department of Life Sciences, Birmingham City University, Birmingham B15 3TN, UK $1 https://orcid.org/0000000302358447
700    1_
$a Pucci, Perla $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK $1 https://orcid.org/0000000312643487
700    1_
$a Amos Burke, G A $u Department of Paediatric Oncology, Cambridge University Hospital NHS Trust, Cambridge CB5 8PD, UK
700    1_
$a Monahan, Jack $u The European Bioinformatics Institute (EMBL EBI), Wellcome Genome Campus, Cambridge CB10 1SA, UK
700    1_
$a Lai, Raymond $u Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, Canada $1 https://orcid.org/0000000269632407
700    1_
$a Merkel, Olaf $u Department of Pathology, Medical University Vienna, 1090 Vienna, Austria
700    1_
$a Schiefer, Ana-Iris $u Department of Pathology, Medical University Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000335558672
700    1_
$a Kenner, Lukas $u Department of Pathology, Medical University Vienna, 1090 Vienna, Austria $u Unit of Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, 1210 Vienna, Austria $u CBMed, 8010 Graz, Austria $u Christian Doppler Laboratory of Applied Metabolomics (CDL-AM), Medical University Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000321841338
700    1_
$a Bannister, Andrew J $u The Gurdon Institute, Cambridge CB2 1QN, UK $1 https://orcid.org/0000000263124436
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK $u Central European Institute of Technology (CEITEC), Masaryk University, 601 77 Brno, Czech Republic $1 https://orcid.org/0000000284394507
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35008316 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131813 $b ABA008
999    __
$a ind $b bmc $g 1784569 $s 1161563
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 14 $c 1 $e 20211229 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a C9685/A25117 $p Cancer Research UK $2 United Kingdom
GRA    __
$a 675712 $p Marie Curie $2 United Kingdom
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Možnosti archivace